drugset

drugset / Trial / NCT01619033

Pharmacokinetics of BF2.649 in Renal Impairment

NCT01619033 ↗

Phase 1 Completed 25 enrolled Bioprojet

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is an open, parallel group study in subjects with normal renal function compared to those with renal dysfunction.

Timeline

Start: 2011-07
Primary completion: 2012-11
Completion: 2012-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pitolisant	Small molecule	20 mg	Oral

Indications